Republic Healthcare Limited reported FY2025 revenue of S$7.96 million, down 8.1% from S$8.66 million in FY2024. Treatment services contributed 60.3% of turnover, medical investigation 26.0% and consultation 13.4%; a nascent education segment added S$0.01 million.

The group recorded a net loss of S$3.01 million versus a S$0.18 million loss a year earlier. Management cited stiffer competition in Singapore’s primary-care market, inflation-led cost pressures and early-stage expenses for China and education ventures. Other operating expenses climbed 46.9% to S$2.85 million, employee costs rose to S$4.84 million, and finance costs more than doubled to S$0.10 million on higher lease liabilities.

Cash used in operations totalled S$2.00 million, swinging from a S$0.13 million inflow in FY2024. Capital expenditure, including new clinics and an investment property, reached S$6.78 million. Year-end cash and cash equivalents stood at S$6.41 million, down from S$11.37 million.

Total assets were S$16.14 million, with right-of-use assets expanding to S$4.97 million following new leases. Net assets fell to S$9.55 million, while the gearing ratio (lease liabilities to equity) widened to 53% from 6%. The board proposed no dividend for FY2025.

Looking ahead, management plans to streamline Singapore operations and continue developing its China healthcare and regional education initiatives, while maintaining cost discipline and liquidity.